Journal
VIROLOGICA SINICA
Volume 37, Issue 6, Pages 786-795Publisher
KEAI PUBLISHING LTD
DOI: 10.1016/j.virs.2022.11.007
Keywords
SARS-CoV-2; Omicron; Vaccine; Antibody evasion; Cellular immunity
Categories
Funding
- National Science and Technology Major Project of China
- Applied Basic and Frontier Technology Research Project of Wuhan
- Key Biosafety Science and Technology Program of Hubei Jiangxia Lab-oratory
- [92169121]
- [2020020601012233]
- [JXBS001]
Ask authors/readers for more resources
The newly discovered SARS-CoV-2 variant Omicron has become a global health concern due to its significant antibody evasion properties. However, the third booster vaccine dose can enhance neutralizing antibody levels and the vaccine-induced cellular response serves as a second-line defense against Omicron.
The recently discovered SARS-CoV-2 variant Omicron (B.1.1.529) has rapidly become a global public health issue. The substantial mutations in the spike protein in this new variant have raised concerns about its ability to escape from pre-existing immunity established by natural infection or vaccination. In this review, we give a summary of current knowledge concerning the antibody evasion properties of Omicron and its subvariants (BA.2, BA.2.12.1, BA.4/5, and BA.2.75) from therapeutic monoclonal antibodies and the sera of SARS-CoV-2 vaccine recipients or convalescent patients. We also summarize whether vaccine-induced cellular immunity (memory B cell and T cell response) can recognize Omicron specifically. In brief, the Omicron variants demonstrated remarkable antibody evasion, with even more striking antibody escape seen in the Omicron BA.4 and BA.5 sub-lineages. Luckily, the third booster vaccine dose significantly increased the neutralizing antibodies titers, and the vaccine-induced cellular response remains conserved and provides second-line defense against the Omicron.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available